Pay in 4 interest-free payments of $6.90 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
reassess after several weeks using objective logs and patient-reported feedback
NEJM 2023: 10.1056/NEJMoa2301972 Phase 2 dose-response (1, 4, 8, 12 mg arms, 48 wk, non-diabetic obesity)
Published: October 13, 2009 Copyright: 2009 Mileo et al
Western blot analysis of thoracic aorta proteins showed that the classic aging markers P21 and P16 were significantly downregulated following FOXO4-DRI treatment, whereas the expression levels of the cell proliferation marker Ki-67 and Lamin B, a key protein involved in nuclear structural stability, were markedly upregulated (Figure 1A)
US$ 26.41
US$ 25.24
US$ 22.19
US$ 28.72
